Teva Pharmaceutical Industries' chairman Yitzhak Peterburg has been appointed interim president and chief executive officer.
“The company is focusing on executing its strategic priorities to transform Teva with immediate focus on realizing the cost synergies and strategic benefits of the Actavis Generics acquisition,” Peterburg said. “I look forward to working with the entire Teva team to conduct a thorough review of the business to find additional opportunities to enhance value for shareholders.”
Peterburg's promotion comes after Erez Vigodman stepped down as the company’s president.
“I believe that now is the right time for me to step down,” Vigodman said. “It has been a privilege to lead Teva, and I am proud of all we have accomplished. I am confident that the company’s future is bright.”